NOT-AG-19-021: Notice of Change to PAR-18-186, "Development of Socially-Assistive Robots (SARs) to Engage Persons with Alzheimer's Disease (AD) and AD-Related Dementias (ADRD), and their Caregivers (R43/R44 Clinical Trial Optional)"

Notice of Change to PAR-18-186, "Development of Socially-Assistive Robots (SARs) to Engage Persons with Alzheimer's Disease (AD) and AD-Related Dementias (ADRD), and their Caregivers (R43/R44 Clinical Trial Optional)"

Notice Number: NOT-AG-19-021

Key Dates
Release Date: April 15, 2019

Related Announcements
PAR-18-186

Issued by
National Institute on Aging (NIA)

Purpose

This Notice clarifies that for PAR-18-186, the inclusion of a commercialization plan is only required for Phase II, Fast-Track, and Phase IIB applications; a commercialization plan is not required for Phase I applications.

The following section of PAR-18-186 is changed as specified below:

Part 2, Section IV. Application and Submission Information

2. Content and Form of Application Submission, SBIR/STTR Information

Currently reads:

Commercialization Plan: All applicants are expected to describe a realistic plan (extending beyond the Phase II), which outlines how and when full commercialization can be accomplished. The full commercialization of the product/technology should be carried out with non-STTR funds.

Modified to:

Commercialization Plan: Phase II, Fast-Track, and Phase IIB applicants are expected to describe a realistic plan (extending beyond the Phase II), which outlines how and when full commercialization can be accomplished. The full commercialization of the product/technology should be carried out with non-STTR funds.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Michael-David A.R.R. Kerns, M.M., M.S. Ph.D.
National Institute on Aging (NIA)
Telephone: 301-402-7713
Email: kernsmd@mail.nih.gov